Renin-Angiotensin-System (RAS)-Acting Agents Global Market Report 2025

Description

Renin-angiotensin system (RAS)-acting agents are a group of medications designed to regulate blood pressure, fluid balance, and vascular resistance by targeting different components of the renin-angiotensin system, which plays a vital role in cardiovascular and renal function. These agents are frequently prescribed for conditions such as hypertension, heart failure, and chronic kidney disease, either by blocking the production of angiotensin II or inhibiting its effects on blood vessels.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary classes of drugs in the renin-angiotensin system (RAS)-acting agents include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), renin inhibitors, aldosterone antagonists, and others. ACE inhibitors are medications that block the enzyme responsible for converting angiotensin I into angiotensin II, a substance that narrows blood vessels and raises blood pressure. They are used for various indications such as hypertension, heart failure, chronic kidney disease, diabetic nephropathy, and coronary artery disease. These drugs are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and specialty clinics, catering to various end users, including hospitals, research institutes, pharmaceutical companies, and others.

The renin-angiotensin-system (RAS)-acting agents market research report is one of a series of new reports from The Business Research Company that provides renin-angiotensin-system (RAS)-acting agents market statistics, including renin-angiotensin-system (RAS)-acting agents industry global market size, regional shares, competitors with a renin-angiotensin-system (RAS)-acting agents market share, detailed renin-angiotensin-system (RAS)-acting agents market segments, market trends and opportunities, and any further data you may need to thrive in the renin-angiotensin-system (RAS)-acting agents industry. This renin-angiotensin-system (RAS)-acting agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The renin-angiotensin-system (RAS)-acting agents market size has grown strongly in recent years. It will grow from$5.82 billion in 2024 to $6.17 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth during the historic period can be attributed to several factors, including the rising prevalence of hypertension, the increasing incidence of cardiovascular diseases, the growing aging population, heightened awareness about blood pressure management, strong support from clinical research, and regulatory approvals for new drugs.

The renin-angiotensin-system (RAS)-acting agents market size is expected to see strong growth in the next few years. It will grow to$7.73 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth during the forecast period can be attributed to several factors, including an increasing focus on personalized treatment, higher demand for fixed-dose combinations, greater investment in cardiovascular research, expanding healthcare access in emerging markets, and the rising prevalence of lifestyle-related diseases. Key trends during this period include AI-driven drug development, nanotechnology-based drug delivery, advancements in personalized medicine, the use of blockchain for secure clinical data, wearable biosensors for hypertension monitoring, and the application of digital twin technology for patient modeling.

The growing prevalence of hypertension is expected to drive the expansion of the renin-angiotensin system (RAS)-acting agents market in the coming years. Hypertension, or high blood pressure, is a chronic condition in which the force of blood against the artery walls is consistently too high. The rise in hypertension is largely due to unhealthy diets, particularly those rich in salt and processed foods, which contribute to higher blood pressure and increased strain on the cardiovascular system. RAS-acting agents help mitigate hypertension by regulating blood pressure through the inhibition of angiotensin II, a hormone that constricts blood vessels and increases fluid retention. By promoting vasodilation and reducing blood pressure, these agents help manage hypertension. For example, in October 2024, the Australian Bureau of Statistics reported that 11.6% (3.0 million) of Australians had hypertension in 2022, with similar rates observed for males (11.7%) and females (11.6%). Thus, the rising prevalence of hypertension is driving the growth of the RAS-acting agents market.

Key players in the RAS-acting agents market are focusing on developing novel inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors, to improve efficacy, minimize side effects, enhance patient compliance, and address hypertension, heart failure, and kidney diseases. ACE inhibitors work by lowering blood pressure through the blockage of the enzyme responsible for converting angiotensin I to angiotensin II, a substance that narrows blood vessels. For example, in November 2023, Proveca Ltd., a UK-based pharmaceutical company, received a grant from the European Commission for pediatric use marketing authorization (PUMA) for Aqumeldi (enalapril maleate) orodispersible tablets, which are indicated for the treatment of heart failure in children aged from birth to under 18 years. Aqumeldi, an ACE inhibitor, treats pediatric heart failure by preventing the conversion of angiotensin I to angiotensin II, thereby relaxing blood vessels, improving blood flow, and reducing the heart's workload.

In February 2023, AstraZeneca, a UK-based pharmaceutical company, acquired CinCor Pharma for $1.3 billion. Through this acquisition, AstraZeneca aims to strengthen its cardiorenal pipeline by adding CinCor's lead drug, baxdrostat (CIN-107), a selective aldosterone synthase inhibitor (ASI) designed to reduce blood pressure in treatment-resistant hypertension. CinCor Pharma, a U.S.-based biopharmaceutical company, is focused on developing RAS-acting agents, including baxdrostat, which targets resistant hypertension.

Major players in the renin-angiotensin-system (RAS)-acting agents market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sandoz International GmbH, Astellas Pharma Inc., Bausch Health Companies Inc., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Biocon Limited, Daiichi Sankyo Company Limited, Glenmark Pharmaceuticals Ltd., and Torrent Pharmaceuticals Ltd.

North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in renin-angiotensin system (RAS)-acting agents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the renin-angiotensin system (RAS)-acting agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The renin-angiotensin system (RAS)-acting agents market consists of sales of enalapril, lisinopril, ramipril, and captopril. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Renin-Angiotensin-System (RAS)-Acting Agents Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on renin-angiotensin-system (ras)-acting agents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for renin-angiotensin-system (ras)-acting agents ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The renin-angiotensin-system (ras)-acting agents market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers (ARBs); Renin Inhibitors; Aldosterone Antagonists; Other Drug Classes
2) By Indication: Hypertension; Heart Failure; Chronic Kidney Disease; Diabetic Nephropathy; Coronary Artery Disease
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Clinics
4) By End-User: Hospitals; Research Institutes; Pharmaceutical Companies; Other End-Users
Subsegments:
1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril; Enalapril; Lisinopril; Ramipril; Perindopril
2) By Angiotensin II Receptor Blockers (ARBs): Losartan; Valsartan; Irbesartan; Olmesartan; Telmisartan
3) By Renin Inhibitors: Aliskiren
4) By Aldosterone Antagonists: Spironolactone; Eplerenone
5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs); Endothelin Receptor Antagonists; Vasopeptidase Inhibitors; Mineralocorticoid Receptor Antagonists (MRAs); Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)
Companies Mentioned: Pfizer Inc.; Merck And Co. Inc.; Bayer AG; Sanofi S.A.; Bristol-Myers Squibb Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r34948

1. Executive Summary

2. Renin-Angiotensin-System (RAS)-Acting Agents Market Characteristics

3. Renin-Angiotensin-System (RAS)-Acting Agents Market Trends And Strategies

4. Renin-Angiotensin-System (RAS)-Acting Agents Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Renin-Angiotensin-System (RAS)-Acting Agents Growth Analysis And Strategic Analysis Framework

5.1. Global Renin-Angiotensin-System (RAS)-Acting Agents PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Renin-Angiotensin-System (RAS)-Acting Agents Market Growth Rate Analysis
5.4. Global Renin-Angiotensin-System (RAS)-Acting Agents Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Renin-Angiotensin-System (RAS)-Acting Agents Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Renin-Angiotensin-System (RAS)-Acting Agents Total Addressable Market (TAM)

6. Renin-Angiotensin-System (RAS)-Acting Agents Market Segmentation

6.1. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Angiotensin-Converting Enzyme (ACE) Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Renin Inhibitors
Aldosterone Antagonists
Other Drug Classes
6.2. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hypertension
Heart Failure
Chronic Kidney Disease
Diabetic Nephropathy
Coronary Artery Disease
6.3. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Specialty Clinics
6.4. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Research Institutes
Pharmaceutical Companies
Other End-Users
6.5. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Captopril
Enalapril
Lisinopril
Ramipril
Perindopril
6.6. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Sub-Segmentation Of Angiotensin II Receptor Blockers (ARBs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Losartan
Valsartan
Irbesartan
Olmesartan
Telmisartan
6.7. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Sub-Segmentation Of Renin Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Aliskiren
6.8. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Sub-Segmentation Of Aldosterone Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Spironolactone
Eplerenone
6.9. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs)
Endothelin Receptor Antagonists
Vasopeptidase Inhibitors
Mineralocorticoid Receptor Antagonists (MRAs)
Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)

7. Renin-Angiotensin-System (RAS)-Acting Agents Market Regional And Country Analysis

7.1. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agents Market

8.1. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Renin-Angiotensin-System (RAS)-Acting Agents Market

9.1. China Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
9.2. China Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Renin-Angiotensin-System (RAS)-Acting Agents Market

10.1. India Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Renin-Angiotensin-System (RAS)-Acting Agents Market

11.1. Japan Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
11.2. Japan Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Renin-Angiotensin-System (RAS)-Acting Agents Market

12.1. Australia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Renin-Angiotensin-System (RAS)-Acting Agents Market

13.1. Indonesia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Renin-Angiotensin-System (RAS)-Acting Agents Market

14.1. South Korea Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
14.2. South Korea Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Renin-Angiotensin-System (RAS)-Acting Agents Market

15.1. Western Europe Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
15.2. Western Europe Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Renin-Angiotensin-System (RAS)-Acting Agents Market

16.1. UK Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Renin-Angiotensin-System (RAS)-Acting Agents Market

17.1. Germany Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Renin-Angiotensin-System (RAS)-Acting Agents Market

18.1. France Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Renin-Angiotensin-System (RAS)-Acting Agents Market

19.1. Italy Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Renin-Angiotensin-System (RAS)-Acting Agents Market

20.1. Spain Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Renin-Angiotensin-System (RAS)-Acting Agents Market

21.1. Eastern Europe Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
21.2. Eastern Europe Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Renin-Angiotensin-System (RAS)-Acting Agents Market

22.1. Russia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Renin-Angiotensin-System (RAS)-Acting Agents Market

23.1. North America Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
23.2. North America Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Renin-Angiotensin-System (RAS)-Acting Agents Market

24.1. USA Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
24.2. USA Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Renin-Angiotensin-System (RAS)-Acting Agents Market

25.1. Canada Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
25.2. Canada Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Renin-Angiotensin-System (RAS)-Acting Agents Market

26.1. South America Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
26.2. South America Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Renin-Angiotensin-System (RAS)-Acting Agents Market

27.1. Brazil Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Renin-Angiotensin-System (RAS)-Acting Agents Market

28.1. Middle East Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
28.2. Middle East Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Renin-Angiotensin-System (RAS)-Acting Agents Market

29.1. Africa Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
29.2. Africa Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Renin-Angiotensin-System (RAS)-Acting Agents Market Competitive Landscape And Company Profiles

30.1. Renin-Angiotensin-System (RAS)-Acting Agents Market Competitive Landscape
30.2. Renin-Angiotensin-System (RAS)-Acting Agents Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Renin-Angiotensin-System (RAS)-Acting Agents Market Other Major And Innovative Companies

31.1. AstraZeneca plc
31.2. Novartis AG
31.3. GSK plc
31.4. Teva Pharmaceutical Industries Ltd.
31.5. Boehringer Ingelheim GmbH
31.6. Sandoz International GmbH
31.7. Astellas Pharma Inc.
31.8. Bausch Health Companies Inc.
31.9. Aurobindo Pharma Limited
31.10. Cipla Limited
31.11. Dr. Reddy's Laboratories Ltd.
31.12. Biocon Limited
31.13. Daiichi Sankyo Company Limited
31.14. Glenmark Pharmaceuticals Ltd.
31.15. Torrent Pharmaceuticals Ltd.

32. Global Renin-Angiotensin-System (RAS)-Acting Agents Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Renin-Angiotensin-System (RAS)-Acting Agents Market

34. Recent Developments In The Renin-Angiotensin-System (RAS)-Acting Agents Market

35. Renin-Angiotensin-System (RAS)-Acting Agents Market High Potential Countries, Segments and Strategies

35.1 Renin-Angiotensin-System (RAS)-Acting Agents Market In 2029 - Countries Offering Most New Opportunities
35.2 Renin-Angiotensin-System (RAS)-Acting Agents Market In 2029 - Segments Offering Most New Opportunities
35.3 Renin-Angiotensin-System (RAS)-Acting Agents Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer
250617_r34948_Renin_Angiotensin_System_RAS_Acting_Agents_GMR_2025